

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 09/599,760		ATTY. DOCKET NO.: V0139.70059US00	
		FILING DATE: June 22, 2000		CONFIRMATION NO.: 8006	
		APPLICANT: Martha Karen Newell			
		GROUP ART UNIT: 1635		EXAMINER: Jane J. Zara	
Sheet	1	of	1		

#### U.S. PATENT DOCUMENTS


Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
J3 ↓	A1	2003/0150022	A1	Newell et al.	08-07-2003
	A2	2004/00054291	A1	Rogers et al.	01-08-2004
	A3	2005/0042224	A1	Newell	02-24-2005
	A4	2005/0074882	A1	Newell	04-07-2005
	A5	2005/0158333	A1	Newell	07-02-2005

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
J3 ↓	B1	WO	00/78941	A2	Newell	12/28/2000	
	B2	WO	03/031643	A2	Newell et al.	04/17/2003	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
J3 ↓	C1	BURROWS, F.J. et al. "A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors," <i>Cancer Research</i> , 52(21), 11/1/92, pg. 5954-62, Abstract		
	C2	ELIOPOULOS, AG et al. "CD40 Stimulation Augments Apoptosis In Carcinoma Cell Lines," <i>J. Cellular Biochem</i> , (supplemental 19B), Abstract B8-123, pg. 271, 1995		
	C3	MORIMOTO, H. et al. "Overcoming Tumor Necrosis Factor and Drug Resistance of Humor Tumor Cell Lines by Combination Treatment with Anti-Fas Antibody and Drugs or Toxins," <i>Cancer Research</i> , 53(11), pp: 2591-2596, 1993		

EXAMINER: 	DATE CONSIDERED: 11-16-05
---	---------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]